Welgene Biotech Co., Ltd. (6661) AI Stock Analysis

Welgene Biotech Co., Ltd.

(TPEx:6661)

Select Model

Rating:44Neutral

Price Target:TWD 15.50▼(-3.13% Downside)

Action:initiatedcoverage

Date:11/10/26

Weak profitability and inconsistent cash generation are the primary risks, reinforced by rising leverage. Technical momentum is also weak, while the negative P/E provides no valuation support, resulting in a low overall stock score.

Positive Factors

Revenue ReboundThe sharp 2025 revenue rebound shows that Welgene can regain demand after a softer period, supporting its ability to scale testing and laboratory services. If sustained, stronger volume can improve utilization, expand customer reach, and provide a larger base for future operating leverage.

Negative Factors

Thin ProfitabilityVery thin profitability leaves little buffer against cost increases, volume volatility, or changes in testing mix. Near-breakeven operating profit also indicates limited operating leverage today, making it harder for revenue growth to translate into durable earnings and internally funded expansion.

Welgene Biotech Co., Ltd. (6661) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 372.87M
Dividend Yield: ―
Average Volume (3M): 5,950
Price to Earnings (P/E): -234.3
Beta (1Y): 0.29
Revenue Growth: 15.25%
EPS Growth: -171.60%
Country: TW
Employees: 80
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Welgene Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysi...

Welgene Biotech Co., Ltd. Financial Statement Overview

Summary

Revenue recovered, equity remains positive, and operating cash flow is positive, but profitability is extremely weak, leverage has increased, operating cash flow declined, and free cash flow turned negative.

Income Statement

45Neutral

Balance Sheet

58Neutral

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	398.92M	375.94M	322.55M	280.55M	321.90M	312.65M
Gross Profit	144.89M	129.27M	135.84M	119.72M	141.80M	133.27M
EBITDA	30.93M	27.92M	33.01M	26.84M	35.66M	39.12M
Net Income	-1.64M	1.33M	1.11M	-2.65M	9.55M	13.70M
Balance Sheet
Total Assets	658.59M	622.19M	528.25M	548.16M	435.71M	424.54M
Cash, Cash Equivalents and Short-Term Investments	201.99M	269.03M	228.19M	197.83M	218.36M	224.26M
Total Debt	281.15M	226.03M	129.83M	154.35M	51.19M	23.84M
Total Liabilities	380.96M	336.12M	232.50M	247.89M	131.76M	114.47M
Stockholders Equity	273.14M	281.30M	287.91M	292.03M	303.76M	309.86M
Cash Flow
Free Cash Flow	-102.42M	-6.08M	51.27M	-28.10M	24.57M	6.87M
Operating Cash Flow	29.09M	35.27M	56.08M	-366.00K	51.43M	11.25M
Investing Cash Flow	-127.35M	-35.74M	-45.19M	6.00M	-67.99M	-10.34M
Financing Cash Flow	85.35M	51.31M	-25.52M	23.91M	-24.61M	38.52M

Welgene Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6661 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4183	46Neutral	TWD 345.10M	-13.92	―	4.62%	-23.50%	-73.10%
TW:6661	44Neutral	TWD 372.87M	-234.26	―	―	15.25%	-171.60%

* General Sector Average

Performance Comparison

TW:6661 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6661	Welgene Biotech Co., Ltd.	16.00	-2.75	-14.67%
TW:4117	General Biologicals Corp.	7.41	-5.04	-40.48%
TW:4183	EPS Bio Technology Corp.	14.50	-3.50	-19.44%
TW:6660	HMD Biomedical, Inc.	12.70	-11.05	-46.53%
TW:6848	RBC Bioscience Corporation	20.95	6.38	43.76%
TW:7595	Pharmigene, Inc.	8.20	-2.80	-25.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Welgene Biotech Co., Ltd. AI Stock Analysis